In particular, we showed that AXL and GAS6 overexpression is a molecular trait of approximately 70% of CRC with a different degree of expression, evaluated by IHC, with a statistical significant correlation between the ligand and receptor. This evidence concerns the gene AXL and colorectal carcinoma.